138 related articles for article (PubMed ID: 36883805)
21. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
22. [Cerebriform variant type of T cell prolymphocytic leukemia: Report of one case].
Peña C; Valladares X; Soto C; Encina A; Marinov N; Undurraga MS; Cabrera ME
Rev Med Chil; 2016 Jan; 144(1):124-8. PubMed ID: 26998991
[TBL] [Abstract][Full Text] [Related]
23. Multiple karyotypic abnormalities in three cases of small cell variant of T-cell prolymphocytic leukemia.
Heinonen K; Mahlamäki E; Hämäläinen E; Nousiainen T; Mononen I
Cancer Genet Cytogenet; 1994 Nov; 78(1):28-35. PubMed ID: 7987802
[TBL] [Abstract][Full Text] [Related]
24. Immunophenotyping of mature T/NK cell neoplasm presenting as leukemia.
Gujral S; Polampalli S; Badrinath Y; Kumar A; Subramanian PG; Nair R; Sengar M; Nair C
Indian J Cancer; 2010; 47(2):189-93. PubMed ID: 20448385
[TBL] [Abstract][Full Text] [Related]
25. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
[TBL] [Abstract][Full Text] [Related]
26. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
[TBL] [Abstract][Full Text] [Related]
27. T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis.
Yoshioka Y; Nagao M; Saitoh T; Yoshioka S; Tsunemine H; Itoh K; Kodaka T; Takahashi T
J Clin Exp Hematop; 2015; 55(1):17-21. PubMed ID: 26106002
[TBL] [Abstract][Full Text] [Related]
28. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
[TBL] [Abstract][Full Text] [Related]
29. T-cell Prolymphocytic Leukemia.
Matutes E
Cancer Control; 1998 Jan; 5(1):19-24. PubMed ID: 10761013
[TBL] [Abstract][Full Text] [Related]
30. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P; Aoki E; Keating M; Wierda WG; O'Brien S; Gonzalez GN; Ferrajoli A; Jain N; Thompson PA; Jabbour E; Kanagal-Shamanna R; Pierce S; Alousi A; Hosing C; Khouri I; Estrov Z; Cortes J; Kantarjian H; Ravandi F; Kadia TM
Ann Oncol; 2017 Jul; 28(7):1554-1559. PubMed ID: 28379307
[TBL] [Abstract][Full Text] [Related]
31. [Cutaneous localization of T-cell prolymphocytic leukemia].
Thomas A; Dompmartin A; Troussard X; Moreau A; Manard C; Leroy D
Ann Dermatol Venereol; 1995; 122(8):526-9. PubMed ID: 8572493
[TBL] [Abstract][Full Text] [Related]
32. T-cell prolymphocytic leukemia with a novel translocation (6;11)(q21;q23).
Wong KF; Chan JK; Sin VC
Cancer Genet Cytogenet; 1999 Jun; 111(2):149-51. PubMed ID: 10347553
[TBL] [Abstract][Full Text] [Related]
33. Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia.
Miyata A; Kojima K; Yoshino T; Fujii S; Shinagawa K; Ichimura K
Int J Hematol; 2001 Feb; 73(2):230-5. PubMed ID: 11372737
[TBL] [Abstract][Full Text] [Related]
34. [Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].
Maeda A; Iwai K; Ishibashi T
Rinsho Ketsueki; 2009 Aug; 50(8):658-62. PubMed ID: 19915381
[TBL] [Abstract][Full Text] [Related]
35. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.
Garand R; Goasguen J; Brizard A; Buisine J; Charpentier A; Claisse JF; Duchayne E; Lagrange M; Segonds C; Troussard X; Flandrin G
Br J Haematol; 1998 Nov; 103(2):488-94. PubMed ID: 9827924
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
[TBL] [Abstract][Full Text] [Related]
37. Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.
Jeong KH; Lew BL; Sim WY
Acta Derm Venereol; 2009; 89(5):509-12. PubMed ID: 19734979
[TBL] [Abstract][Full Text] [Related]
38. Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia?
Pawson R; Matutes E; Brito-Babapulle V; Maljaie H; Hedges M; Mercieca J; Dyer M; Catovsky D
Leukemia; 1997 Jul; 11(7):1009-13. PubMed ID: 9204983
[TBL] [Abstract][Full Text] [Related]
39. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS
Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678
[TBL] [Abstract][Full Text] [Related]
40. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
